Bevacizumab combined with gemcitabine and capecitabine for advanced pancreatic cancer: a phase II study

A total of 50 patients with advanced pancreatic cancer were enrolled in a phase II study of bevacizumab 15 mg kg −1 , capecitabine 1300 mg m −2 daily for 2 weeks and gemcitabine 1000 mg m −2 weekly 2 times; cycles were repeated every 21 days. Radiological response rate was 22%; progression-free surv...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	British journal of cancer 2009-06, Vol.100 (12), p.1842-1845
Hauptverfasser:	Javle, M, Yu, J, Garrett, C, Pande, A, Kuvshinoff, B, Litwin, A, Phelan, J, Gibbs, J, Iyer, R
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Aged, 80 and over Antibodies, Monoclonal - administration & dosage Antibodies, Monoclonal, Humanized Antineoplastic Combined Chemotherapy Protocols - therapeutic use Bevacizumab Biological and medical sciences Biomedical and Life Sciences Biomedicine Cancer Research Capecitabine Deoxycytidine - administration & dosage Deoxycytidine - analogs & derivatives Drug Resistance Epidemiology Female Fluorouracil - administration & dosage Fluorouracil - analogs & derivatives Gastroenterology. Liver. Pancreas. Abdomen Humans Liver Neoplasms - drug therapy Liver Neoplasms - secondary Liver. Biliary tract. Portal circulation. Exocrine pancreas Lung Neoplasms - drug therapy Lung Neoplasms - secondary Lymphatic Metastasis Male Medical sciences Middle Aged Molecular Medicine Oncology Pancreatic cancer Pancreatic Neoplasms - drug therapy Pancreatic Neoplasms - pathology Prognosis Short Communication Survival Rate Treatment Outcome Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	A total of 50 patients with advanced pancreatic cancer were enrolled in a phase II study of bevacizumab 15 mg kg −1 , capecitabine 1300 mg m −2 daily for 2 weeks and gemcitabine 1000 mg m −2 weekly 2 times; cycles were repeated every 21 days. Radiological response rate was 22%; progression-free survival and over survival were 5.8 and 9.8 months respectively. Grade 3 or 4 toxicities included neutropaenia (22%), thrombocytopaenia (14%), thromboembolic events (12%), hypertension (8%) and haemorrhage (6%).
ISSN:	0007-0920 1532-1827
DOI:	10.1038/sj.bjc.6605099